New Manuscript validates Kanzius Laboratory Group is the Worlds First to Deliver Nanoparticles to the Nucleus of a Cancer Cell.
01/26/12
Kanzius Cancer Research Foundation Funds Research at the University of Texas M.D. Anderson Cancer Center, Destroying Cancer Cells with Heated Carbon Nanoparticles
(ERIE, PA) – January 25, 2012 -- Kanzius Cancer Research Foundation (“KCRF”) announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the January 2012 issue of Biomaterials journal. The manuscript illustrates how Drs. Steven A. Curley, Mustafa Raoof, Yuri Mackeyev, Mathew A. Cheney and Lon J. Wilson’s studies make them the first in the world to prove that they can get carbon nanoparticles into the nucleus of cancer cells. They were able move nanoparticles into the fluid environment around the nucleus (cytoplasm) in prior studies, but never before could they reach the actual nucleus where the DNA of cells is located. Now that they have, it will open the door for the Kanzius radiofrequency field treatment to succeed.
Essentially, DNA in the nucleus is particularly sensitive to heat and if it is damaged and destroyed with the Kanzius radiofrequency field treatment, the cancer cells will die rapidly. The researchers are now working to use the carbon nanoparticles to target cancer cells in animals with pancreatic or liver cancer.
Dr. Curley, Chief of Gastrointestinal Tumor Surgery and Program Director of Multidisciplinary Gastrointestinal Cancer Care at the University of Texas M.D. Anderson Cancer Center, noted, “The carbon nanoparticles are fascinating because they are the smallest particles we have used. It is also possible to attach chemotherapy drugs or other agents to the carbon nanoparticles and have the nanoparticles carry these into the nucleus with them.” Curley also stated that he believes “this will further enhance treatment in the Kanzius radiofrequency field to produce heating of the cancer cell and ultimately, cancer cell death.”
“Every day, our team at the Kanzius Cancer Research Foundation works to help fund this incredible research,” said Mark Neidig, Executive Director of KCRF. “These recent findings bring us another step closer to our goal of producing an effective, noninvasive cancer treatment that doesn’t have the harsh side effects associated with current treatments like chemotherapy and radiation.”
This entire manuscript “Internalization of C60 fullerenes into cancer cells with accumulation
in the nucleus via the nuclear pore complex” can be found in the January 2012 issue of Biomaterials or at www.Kanzius.org/Manuscripts2012.01.
About John Kanzius & Radiowave Treatment Research
John Kanzius (1944-2009) spent his life in broadcast engineering, management, and ownership. When he was diagnosed with a rare form of B-cell leukemia in 2002, he began to draw on his knowledge of broadcast and electrical engineering to envision a better way to treat cancer using physics and radio frequency waves. John’s vision has been confirmed and validated by The University of Texas M.D. Anderson Cancer Center in Houston, the University of Pittsburgh Medical Center, University of California-Davis, and the late Richard Smalley, a Nobel Laureate who won the Nobel Prize for his work with carbon nanoparticles. In 2008, clinical trials proved that pancreatic, liver, and colorectal cancer cells can be destroyed by the Kanzius Noninvasive Radiowave Cancer Treatment. Dr. Steven Curley, lead researcher, began discussions with the FDA in February 2009 to obtain approval for human clinical trials and will meet with them again in 2012 to develop a timeline.
About the Kanzius Cancer Research Foundation
The Kanzius Cancer Research Foundation is a 501(c)(3) non-profit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses through human trials. The goal of KCRF is to raise money to support ongoing research grants. Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic and prostate cancers. For more information about the Kanzius research, visit www.Kanzius.org.
